View in EDS PDF Full Text

Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.

Saved in:
Bibliographic Details
Title: Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
Authors: Maaske J; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Sproule S; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Falsey AR; University of Rochester School of Medicine and Dentistry, Rochester, NY, United States.; Rochester Regional Health, Rochester, NY, United States., Sobieszczyk ME; Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian Columbia University Irving Medical Center, New York, NY, United States., Luetkemeyer AF; Zuckerberg San Francisco General, University of California, San Francisco, San Francisco, CA, United States., Paulsen GC; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.; Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States., Riddler SA; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States., Robb ML; Walter Reed Army Institute of Research, Silver Spring, MD, United States., Rolle CP; Orlando Immunology Center, Orlando, FL, United States., Sha BE; Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States., Tong T; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States., Ahani B; Bioinformatics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Aksyuk AA; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Bansal H; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Egan T; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Jepson B; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Padilla M; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Patel N; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Shoemaker K; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Stanley AM; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Swanson PA; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Wilkins D; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Villafana T; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Green JA; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Kelly EJ; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Source: Frontiers in immunology [Front Immunol] 2023 Jan 13; Vol. 13, pp. 1062067. Date of Electronic Publication: 2023 Jan 13 (Print Publication: 2022).
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36713413
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Maaske+J%22">Maaske J</searchLink>; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Sproule+S%22">Sproule S</searchLink>; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Falsey+AR%22">Falsey AR</searchLink>; University of Rochester School of Medicine and Dentistry, Rochester, NY, United States.; Rochester Regional Health, Rochester, NY, United States.<br /><searchLink fieldCode="AU" term="%22Sobieszczyk+ME%22">Sobieszczyk ME</searchLink>; Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian Columbia University Irving Medical Center, New York, NY, United States.<br /><searchLink fieldCode="AU" term="%22Luetkemeyer+AF%22">Luetkemeyer AF</searchLink>; Zuckerberg San Francisco General, University of California, San Francisco, San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Paulsen+GC%22">Paulsen GC</searchLink>; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.; Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.<br /><searchLink fieldCode="AU" term="%22Riddler+SA%22">Riddler SA</searchLink>; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Robb+ML%22">Robb ML</searchLink>; Walter Reed Army Institute of Research, Silver Spring, MD, United States.<br /><searchLink fieldCode="AU" term="%22Rolle+CP%22">Rolle CP</searchLink>; Orlando Immunology Center, Orlando, FL, United States.<br /><searchLink fieldCode="AU" term="%22Sha+BE%22">Sha BE</searchLink>; Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States.<br /><searchLink fieldCode="AU" term="%22Tong+T%22">Tong T</searchLink>; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.<br /><searchLink fieldCode="AU" term="%22Ahani+B%22">Ahani B</searchLink>; Bioinformatics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Aksyuk+AA%22">Aksyuk AA</searchLink>; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Bansal+H%22">Bansal H</searchLink>; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Egan+T%22">Egan T</searchLink>; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Jepson+B%22">Jepson B</searchLink>; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Padilla+M%22">Padilla M</searchLink>; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Patel+N%22">Patel N</searchLink>; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Shoemaker+K%22">Shoemaker K</searchLink>; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Stanley+AM%22">Stanley AM</searchLink>; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Swanson+PA%22">Swanson PA</searchLink>; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Wilkins+D%22">Wilkins D</searchLink>; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Villafana+T%22">Villafana T</searchLink>; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Green+JA%22">Green JA</searchLink>; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kelly+EJ%22">Kelly EJ</searchLink>; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2023 Jan 13; Vol. 13, pp. 1062067. <i>Date of Electronic Publication: </i>2023 Jan 13 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36713413
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2022.1062067
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1062067
    Titles:
      – TitleFull: Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Maaske J
      – PersonEntity:
          Name:
            NameFull: Sproule S
      – PersonEntity:
          Name:
            NameFull: Falsey AR
      – PersonEntity:
          Name:
            NameFull: Sobieszczyk ME
      – PersonEntity:
          Name:
            NameFull: Luetkemeyer AF
      – PersonEntity:
          Name:
            NameFull: Paulsen GC
      – PersonEntity:
          Name:
            NameFull: Riddler SA
      – PersonEntity:
          Name:
            NameFull: Robb ML
      – PersonEntity:
          Name:
            NameFull: Rolle CP
      – PersonEntity:
          Name:
            NameFull: Sha BE
      – PersonEntity:
          Name:
            NameFull: Tong T
      – PersonEntity:
          Name:
            NameFull: Ahani B
      – PersonEntity:
          Name:
            NameFull: Aksyuk AA
      – PersonEntity:
          Name:
            NameFull: Bansal H
      – PersonEntity:
          Name:
            NameFull: Egan T
      – PersonEntity:
          Name:
            NameFull: Jepson B
      – PersonEntity:
          Name:
            NameFull: Padilla M
      – PersonEntity:
          Name:
            NameFull: Patel N
      – PersonEntity:
          Name:
            NameFull: Shoemaker K
      – PersonEntity:
          Name:
            NameFull: Stanley AM
      – PersonEntity:
          Name:
            NameFull: Swanson PA
      – PersonEntity:
          Name:
            NameFull: Wilkins D
      – PersonEntity:
          Name:
            NameFull: Villafana T
      – PersonEntity:
          Name:
            NameFull: Green JA
      – PersonEntity:
          Name:
            NameFull: Kelly EJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 13
              M: 01
              Text: 2023 Jan 13
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 13
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1